The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint

Momin, Mohammad Yahya; Gaddam, Ravinder Reddy; Kravitz, Madeline; Gupta, Anisha; Vikram, Ajit

doi:10.3390/cells10113097

Open AccessFeature PaperReview

The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint

by

Mohammad Yahya Momin

¹,

Ravinder Reddy Gaddam

²

,

Madeline Kravitz

³,

Anisha Gupta

³

and

Ajit Vikram

^2,*

¹

Mylan Laboratories Ltd. R&D Centre, Bangalore 560105, Karnataka, India

²

Division of Cardiovascular Medicine, Department of Internal Medicine, Carver College of Medicine, The University of Iowa, Iowa City, IA 52242, USA

³

Department of Pharmaceutical Sciences, University of Saint Joseph, West Hartford, CT 06117, USA

^*

Author to whom correspondence should be addressed.

Cells 2021, 10(11), 3097; https://doi.org/10.3390/cells10113097

Submission received: 15 September 2021 / Revised: 22 October 2021 / Accepted: 2 November 2021 / Published: 9 November 2021

(This article belongs to the Collection microRNAs in Health and Diseases)

Download

Browse Figures

Review Reports Versions Notes

Abstract

microRNAs (miRs) are emerging as attractive therapeutic targets because of their small size, specific targetability, and critical role in disease pathogenesis. However, <20 miR targeting molecules have entered clinical trials, and none progressed to phase III. The difficulties in miR target identification, the moderate efficacy of miR inhibitors, cell type-specific delivery, and adverse outcomes have impeded the development of miR therapeutics. These hurdles are rooted in the functional complexity of miR’s role in disease and sequence complementarity-dependent/-independent effects in nontarget tissues. The advances in understanding miR’s role in disease, the development of efficient miR inhibitors, and innovative delivery approaches have helped resolve some of these hurdles. In this review, we provide a multidisciplinary viewpoint on the challenges and opportunities in the development of miR therapeutics.

Keywords: peptide nucleic acids; miR delivery; miRNA; plant-derived miRs

Graphical Abstract

Share and Cite

MDPI and ACS Style

Momin, M.Y.; Gaddam, R.R.; Kravitz, M.; Gupta, A.; Vikram, A. The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint. Cells 2021, 10, 3097. https://doi.org/10.3390/cells10113097

AMA Style

Momin MY, Gaddam RR, Kravitz M, Gupta A, Vikram A. The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint. Cells. 2021; 10(11):3097. https://doi.org/10.3390/cells10113097

Chicago/Turabian Style

Momin, Mohammad Yahya, Ravinder Reddy Gaddam, Madeline Kravitz, Anisha Gupta, and Ajit Vikram. 2021. "The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint" Cells 10, no. 11: 3097. https://doi.org/10.3390/cells10113097

APA Style

Momin, M. Y., Gaddam, R. R., Kravitz, M., Gupta, A., & Vikram, A. (2021). The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint. Cells, 10(11), 3097. https://doi.org/10.3390/cells10113097

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI